SCHEMBL18742103

SCHEMBL18742103

O=S(=O)(O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)O[C@@H]2COS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O

nearest known ligand 0.76

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FGF1 P05230 7/20 0.76
FGF2 P09038 4/20 0.76
HPSE Q9Y251 14/20 0.61
SERPINC1 P01008 2/20 0.54
VEGFA P15692 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18742104 1.00 FGF1 (0.76) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL7311357 1.00 FGF1 (0.76) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL14020073 0.95 FGF1 (0.70) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL4904646 0.95 FGF1 (0.70) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL4906384 0.95 FGF1 (0.70) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL4180806 0.92 FGF1 (0.69) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL14020078 0.90 FGF1 (0.64) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL14020074 0.90 FGF1 (0.64) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL14020081 0.90 FGF1 (0.64) FGF1FGF2HPSESERPINC1VEGFA
SCHEMBL16316488 0.90 FGF1 (0.64) FGF1FGF2HPSESERPINC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647126-A2 STABILIZING CAMPTOTHECIN PHARMACEUTICAL COMPOSITIONS Ipsen Biopharm Ltd. (GB) 2025-11-12 EP disclosed
US-20250152578-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2025-05-15 US disclosed
US-20250000796-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2025-01-02 US disclosed
US-12059497-B2 Stabilizing camptothecin pharmaceutical compositions IPSEN BIOPHARM LTD. (GB) 2024-08-13 US disclosed
US-20230108934-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2023-04-06 US disclosed
CN-114099437-A Stable camptothecin pharmaceutical compositions 易普森生物制药有限公司 2022-03-01 CN disclosed
CN-114073678-A Stable camptothecin pharmaceutical compositions 易普森生物制药有限公司 2022-02-22 CN disclosed
CN-108366965-B Stable camptothecin pharmaceutical compositions 易普森生物制药有限公司 2021-10-01 CN disclosed
US-20210228567-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2021-07-29 US disclosed
US-20210205219-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2021-07-08 US disclosed
US-20200179371-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2020-06-11 US disclosed
US-20200069586-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2020-03-05 US disclosed
US-10456360-B2 Stabilizing camptothecin pharmaceutical compositions IPSEN BIOPHARM LTD. (GB) 2019-10-29 US disclosed
US-20190262331-A9 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2019-08-29 US disclosed
US-20190105317-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2019-04-11 US disclosed
US-20180296484-A1 Stabilizing Camptothecin Pharmaceutical Compositions IPSEN BIOPHARM LTD. (GB) 2018-10-18 US disclosed
EP-3362049-A1 STABILIZING CAMPTOTHECIN PHARMACEUTICAL COMPOSITIONS Ipsen Biopharm Ltd. (GB) 2018-08-22 EP disclosed
US-20180110771-A1 Liposomal Irinotecan Preparations IPSEN BIOPHARM LTD (GB) 2018-04-26 US disclosed
US-20170319573-A1 Stabilizing Camptothecin Pharmaceutical Compositions MERRIMACK PHARMACEUTICALS, INC. 2017-11-09 US disclosed
WO-2017066726-A1 STABILIZING CAMPTOTHECIN PHARMACEUTICAL COMPOSITIONS MERRIMACK PHARMACEUTICALS, INC. (US) 2017-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296484-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20190105317-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-12059497-B2 Stabilizing camptothecin pharmaceutical compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20190262331-A9 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20200069586-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20180110771-A1 Liposomal Irinotecan Preparations PHOSPHO1, PCTP, LCLAT1 FGF1 4496/4885FGF2 4156/4885HPSE 1103/4885
US-10456360-B2 Stabilizing camptothecin pharmaceutical compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20250152578-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4548/4885FGF2 4235/4885HPSE 1859/4885
US-20230108934-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20200179371-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20210205219-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20250000796-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4530/4885FGF2 4229/4885HPSE 1857/4885
US-20210228567-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885
US-20170319573-A1 Stabilizing Camptothecin Pharmaceutical Compositions PHOSPHO1, PCTP, PLTP FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.